Answers are grounded in this paper and cite their sources.
PURPOSE: To evaluate the associations between plasma-soluble Fas ligand (sFasL) and age-related macular degeneration (AMD). METHODS: Plasma samples were obtained from 230 individuals (age range, 45-85), with or without AMD. The concentrations of sFasL were determined by an enzyme-linked immunosorbent assay (ELISA). The measured sFasL levels were transformed into cubic roots and were fitted into linear regression models against AMD status, with adjustment for age and sex. RESULTS: Plasma sFasL increased with age and AMD. There was a linear correlation between age and the cubic roots of sFasL. The plasma sFasL concentrations in non-AMD subjects ranged from 0 to 1.63 ng/mL (median, 0.69 ng/mL), whereas in patients with AMD, sFasL ranged from 0 to 2.43 ng/mL (median, 0.18 ng/mL). Between the ages of 61 and 84, the subjects with AMD had significantly higher sFasL than did the non-AMD subjects. There was a sexual dimorphism of the plasma sFasL levels. In non-AMD subjects, sFasL was lower in the females. In patients with AMD, sFasL was higher in the females. CONCLUSIONS: An elevation of plasma sFasL with aging may play a role in the development of AMD and is a potential peripheral marker for monitoring disease progression.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2008) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: